Literature DB >> 31149230

EFFECT OF EXPERIMENTAL DYSGLYCEMIA ON UNDER-CARBOXYLATED OSTEOCALCIN PRODUCTION IN HUMAN PRIMARY OSTEOBLAST-LIKE CELL CULTURES.

A Kacso1, M Goia-Socol1, G Hazi2, G Tomoaia3,4, I M Kacso5,6, C E Georgescu1,7.   

Abstract

CONTEXT: The undercarboxylated form of osteocalcin (ucOC) and osteoprotegerin (OPG) are bone-derived molecules involved in the endocrine crosstalk governing the bone, the adipose tissue and the pancreas. In addition, glucocorticoids are major determinants of both insulin resistance and osteoporosis.
OBJECTIVE: We aimed to investigate the response of ucOC and OPG to dysglycemia and/or dexamethasone (DXM) in primary human osteoblastic cell (HOC) cultures. DESIGN AND METHODS: Third-passage sub-confluent primary HOC cultures were treated with glucose: 2.8 mmol/L, 5.6 mmol/L, 11.1 mmol/L and 28 mmol/L, respectively. Alternatively, HOC cultures were subjected to DXM 1 μmol/L. In more complex experiments, HOC cultures were pre-treated with glucose (5.6 mmol/L) with/without insulin (1 pmol/L) followed by DXM (1 μmol/L). 24-hours post-treatment, culture medium ucOC and OPG were measured by ELISA.
RESULTS: ucOC production differed significantly (p<0.05) between cell groups, decreasing in a dose-dependent manner as glucose concentration in the medium increased. Insulin prevented this effect. OPG levels appeared not to be significantly influenced by the hyperglycemic culture medium and were not related to ucOC concentration (p>0.05). Addition of DXM resulted in significantly lower ucOC concentrations compared to vehicle-treated cells (p<0.05). However, the effect of insulin co-treatment on ucOC was not counteracted by DXM (p<0.05).
CONCLUSIONS: An obvious alteration of OC production/metabolism was observed as glucose levels changed in the bone microenvironment, to potentially be involved in diabetes-related osteopenia. DXM suppressed ucOC levels however not in insulin-rich environment.

Entities:  

Keywords:  dexamethasone; diabetes mellitus; human osteoblasts; insulin; osteopenia; osteoprotegerin; undercarboxylated osteocalcin

Year:  2018        PMID: 31149230      PMCID: PMC6516604          DOI: 10.4183/aeb.2018.11

Source DB:  PubMed          Journal:  Acta Endocrinol (Buchar)        ISSN: 1841-0987            Impact factor:   0.877


  15 in total

1.  1,25(OH)2D3 inhibits the deleterious effects induced by high glucose on osteoblasts through undercarboxylated osteocalcin and insulin signaling.

Authors:  Ying-ying Wu; Tao Yu; Xiao-hui Zhang; Yan-shan Liu; Feng Li; Yan-ying Wang; Yong-yue Wang; Ping Gong
Journal:  J Steroid Biochem Mol Biol       Date:  2012-05-15       Impact factor: 4.292

2.  New mechanisms of glucocorticoid-induced insulin resistance: make no bones about it.

Authors:  Heather A Ferris; C Ronald Kahn
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

3.  Effects of triiodothyronine on the insulin-like growth factor system in primary human osteoblastic cells in vitro.

Authors:  C E Pepene; C H Kasperk; J Pfeilschifter; I Börcsök; L Gozariu; R Ziegler; T Seck
Journal:  Bone       Date:  2001-12       Impact factor: 4.398

4.  High glucose concentrations alter the biomineralization process in human osteoblastic cells.

Authors:  A García-Hernández; H Arzate; I Gil-Chavarría; R Rojo; L Moreno-Fierros
Journal:  Bone       Date:  2011-11-07       Impact factor: 4.398

Review 5.  New insights into the biology of osteocalcin.

Authors:  Meredith L Zoch; Thomas L Clemens; Ryan C Riddle
Journal:  Bone       Date:  2015-06-06       Impact factor: 4.398

6.  Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways.

Authors:  Sergiu Botolin; Laura R McCabe
Journal:  J Cell Biochem       Date:  2006-10-01       Impact factor: 4.429

7.  Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism.

Authors:  Tara C Brennan-Speranza; Holger Henneicke; Sylvia J Gasparini; Katharina I Blankenstein; Uta Heinevetter; Victoria C Cogger; Dmitri Svistounov; Yaqing Zhang; Gregory J Cooney; Frank Buttgereit; Colin R Dunstan; Caren Gundberg; Hong Zhou; Markus J Seibel
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

Review 8.  Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options.

Authors:  R N J De Nijs
Journal:  Minerva Med       Date:  2008-02       Impact factor: 4.806

9.  Osteocalcin reverses endoplasmic reticulum stress and improves impaired insulin sensitivity secondary to diet-induced obesity through nuclear factor-κB signaling pathway.

Authors:  Bo Zhou; Huixia Li; Lin Xu; Weijin Zang; Shufang Wu; Hongzhi Sun
Journal:  Endocrinology       Date:  2013-02-13       Impact factor: 4.736

Review 10.  Regulation of energy metabolism by the skeleton: osteocalcin and beyond.

Authors:  Mathieu Ferron; Julie Lacombe
Journal:  Arch Biochem Biophys       Date:  2014-06-02       Impact factor: 4.013

View more
  1 in total

1.  OSTEOPOROSIS AND FRACTURE RISK IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.

Authors:  C Poiana; C Capatina
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.